GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Operating Margin %

Viela Bio (Viela Bio) Operating Margin % : -361.31% (As of Dec. 2020)


View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Viela Bio's Operating Income for the three months ended in Dec. 2020 was $-33.73 Mil. Viela Bio's Revenue for the three months ended in Dec. 2020 was $9.34 Mil. Therefore, Viela Bio's Operating Margin % for the quarter that ended in Dec. 2020 was -361.31%.

The historical rank and industry rank for Viela Bio's Operating Margin % or its related term are showing as below:

VIE' s Operating Margin % Range Over the Past 10 Years
Min: -1320.65   Med: -750.02   Max: -179.38
Current: -1320.65


VIE's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -177.195 vs VIE: -1320.65

Viela Bio's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Viela Bio's Operating Income for the three months ended in Dec. 2020 was $-33.73 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2020 was $-153.88 Mil.


Viela Bio Operating Margin % Historical Data

The historical data trend for Viela Bio's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Operating Margin % Chart

Viela Bio Annual Data
Trend Dec18 Dec19 Dec20
Operating Margin %
- -179.38 -1,320.65

Viela Bio Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.34 - - -1,650.22 -361.31

Competitive Comparison of Viela Bio's Operating Margin %

For the Biotechnology subindustry, Viela Bio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viela Bio's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viela Bio's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Viela Bio's Operating Margin % falls into.



Viela Bio Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Viela Bio's Operating Margin % for the fiscal year that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=-153.882 / 11.652
=-1,320.65 %

Viela Bio's Operating Margin % for the quarter that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2020 ) / Revenue (Q: Dec. 2020 )
=-33.732 / 9.336
=-361.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viela Bio  (NAS:VIE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Viela Bio Operating Margin % Related Terms

Thank you for viewing the detailed overview of Viela Bio's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viela Bio (Viela Bio) Business Description

Traded in Other Exchanges
N/A
Address
One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Executives
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu director 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd 10 percent owner SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund 10 percent owner CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao director, officer: Chief Executive Officer 10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz officer: VP, Head of Commercial C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878

Viela Bio (Viela Bio) Headlines

From GuruFocus

Viela Bio Announces Pricing of Public Offering of Common Stock

By GlobeNewswire GlobeNewswire 05-28-2020